CCR2 genotype and disease progression in a treated population of HIV type 1-infected women

Clinical Infectious Diseases

Volumn 39, Issue 6, 2004, Pages 861-865

  Philpott, Sean ^a   Burger, Harold ^a,b   Tarwater, Patrick M ^e   Lu, Ming ^f   Gange, Stephen J ^f   Anastos, Kathryn ^c   Cohen, Mardge ^h   Greenblatt, Ruth M ⁱ   Kovacs, Andrea ^j   Minkoff, Howard ^d   Young, Mary ^k   Miotti, Paolo ^g   Dupuis, Michelle ^a   Weiser, Barbara ^a,b  

^a WADSWORTH CENTER   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h Jr Hospital of Cook County   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j LAC USC MEDICAL CENTER   (United States)

^k GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR2;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DNA POLYMORPHISM; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD; WILD TYPE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; POLYMORPHISM, GENETIC; RECEPTORS, CHEMOKINE; SURVIVAL ANALYSIS;

EID: 4544250408     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/423386     Document Type: Article

References (12)

1. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997; 277:959-65.
2. Michael NL, Louie LG, Rohrbaugh AL, et al. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med 1997; 3:1160-2.
3. Anzala AO, Ball TB, Roston T, et al. CCR2-64I allele and genotype association with delayed AIDS progression in African women. Lancet 1998; 351:1632-3.
4. Ioannidis JPA, Rosenberg PS, Goedert JJ, et al. Effects of CCR5-Δ32, CCR2-64I, and SDF-1 3′ A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med 2001; 135:782-95.
5. Lathey JL, Tierney C, Chang S-YP, et al. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. J Infect Dis 2001; 184:1402-11.
6. + cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med 2004; 140:256-64.
7. CASCADE (Concerted Action on Seroconversion to AIDS and Death in Europe) collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003; 362:1267.
8. Wit FW, Van Rij RP, Weverling GJ, et al. CC chemokine receptor 5 δ 32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients. J Infect Dis 2002; 186:1726-32.
9. O'Brien TR, McDermott DH, Ioannidis JP, et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 2000; 14:821-6.
10. Philpott S, Weiser B, Tarwater P, et al. CCR5 genotype and susceptibility to transmission of HIV-1 in women. J Infect Dis 2003; 187:569-75.
11. Detels R, Tarwater P, Phair JP, et al. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001; 15:347-55.
12. Tarwater PM, Mellors J, Gore ME, et al. Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol 2001; 154:675-81.